ARCT-810

BIOLOGICAL4 trials

Sponsors

Arcturus Therapeutics, Inc.

Conditions

OTC DeficiencyOTCDOrnithine Transcarbamylase Deficiency

Phase 1

Safety, Tolerability and Pharmacokinetics of ARCT-810 in Healthy Adult Subjects

CompletedNCT04416126

Arcturus Therapeutics, Inc.Ornithine Transcarbamylase Deficiency

Start: 2020-06-01End: 2020-12-09Updated: 2023-11-08

Phase 1b Study to Assess Safety, Tolerability, and Pharmacokinetics of ARCT-810 in Stable Adult Subjects With Ornithine Transcarbamylase Deficiency

CompletedNCT04442347

Arcturus Therapeutics, Inc.Ornithine Transcarbamylase Deficiency

Start: 2020-11-03End: 2024-04-30Updated: 2024-08-02

Phase 2

Study for Adolescents and Adults With Ornithine Transcarbamylase Deficiency to Evaluate Safety and Tolerability of ARCT-810

TerminatedNCT05526066

Arcturus Therapeutics, Inc.Ornithine Transcarbamylase Deficiency, OTCD, OTC Deficiency

Start: 2022-10-17End: 2024-10-31Updated: 2025-09-26

A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

RecruitingNCT06488313

Arcturus Therapeutics, Inc.Ornithine Transcarbamylase Deficiency, OTCD, OTC Deficiency

Start: 2024-11-04End: 2026-09-01Target: 9Updated: 2025-03-17